Previous close | 9.690 |
Open | 9.690 |
Bid | 9.510 x N/A |
Ask | 9.690 x N/A |
Day's range | 9.500 - 9.750 |
52-week range | 7.200 - 14.660 |
Volume | |
Avg. volume | 264,704 |
Market cap | 3.173B |
Beta (5Y monthly) | 0.39 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.260 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 15.53 |
Zylox-Tonbridge Medical Technology Co., Ltd. (2190. HK), a leading medical device company in the peripheral and neurovascular interventional market in China, announced its annual financial results for 2023. The report underlines a year of remarkable revenue growth and profitability, with revenues soaring to 530 million RMB ($75 million), marking a 58.0% YOY increase. The gross profit increased 52.4% to 380 million RMB ($54 million), with the company maintaining a solid gross margin of 72.9%. Wit
Zylox-Tonbridge (2190.HK, "the Company"), a leading medical device company in the peripheral and neurovascular interventional market in China, today announced a new strategic partnership with Avinger, a commercial-stage medical device company developing and marketing the first and only intra-vascular image-guided, catheter-based systems for diagnosis and treatment of vascular disease. This partnership includes an exclusive right to Zylox-Tonbridge to localize, manufacture, and commercialize the
Zylox-Tonbridge (2190.HK), a medical device company specializing in peripheral and neurovascular interventions, proudly announces the recent marketing approvals granted by the Ministry of Health and Prevention in the United Arab Emirates for five of its advanced products. These include the ZENFluxion™ Drug-coated PTA Balloon Catheter, ZENFlow™ HP PTA Balloon Catheter, ZENFlow™ PTA Balloon Catheter, ZENFlex™ Peripheral Stent System, and ZENFLEX Pro™ Peripheral Drug-eluting Stent System. This mile